Syndax Pharmaceuticals, which is developing a therapy that enhances checkpoint immuno-oncology drugs, announced terms for its IPO on Monday.
The Waltham, MA-based company plans to raise $66 million by offering 4.4 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Syndax Pharmaceuticals would command a fully diluted market value of $285 million.
The company previously attempted to raise $60 million in a June 2014 IPO.
Syndax Pharmaceuticals was founded in 2005 and booked $1 million in sales for the 12 months ended December 31, 2015. It plans to list on the Nasdaq under the symbol SNDX. Morgan Stanley and Citi are the joint bookrunners on the deal. It is expected to price during the week of February 29, 2016.
